Last reviewed: June 17, 2026

Last updated: June 17, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Wegovy received FDA approval on June 4, 2021, marking a significant shift in how physicians approach chronic weight loss treatment. The injectable semaglutide formulation demonstrated average weight reductions of 15% over 68 weeks in clinical trials. PlexusDx offers compounded semaglutide injections from licensed 503A pharmacies starting at $149 per month, providing access to this proven therapy without insurance requirements.

When Did Wegovy Launch and Gain FDA Approval?

Novo Nordisk submitted semaglutide for weight loss approval in December 2020, and the FDA granted breakthrough therapy designation recognizing its potential impact. On June 4, 2021, the agency approved Wegovy as the first GLP-1 receptor agonist specifically labeled for chronic weight management in adults with obesity or overweight with weight-related comorbidities. This approval represented over a decade of clinical development, building on the drug's established safety profile from its original diabetes indication.

The regulatory pathway for Wegovy included multiple phase 3 trials enrolling over 4,500 participants across diverse populations. These studies consistently showed semaglutide's effectiveness in reducing body weight, improving cardiovascular markers, and enhancing quality of life. The approval transformed weight management from a primary lifestyle-only approach to a medical therapy option backed by robust clinical evidence.

Clinical Trial Results: Weight Loss Outcomes and Real-World Data

The STEP trials (Semaglutide Treatment Effect in People with obesity) demonstrated that participants receiving the highest approved dose lost an average of 15.3% of body weight over 68 weeks compared to 2.6% in the placebo group. In the STEP 1 trial, 86% of patients achieved clinically significant weight loss of at least 5%, while 69% lost 10% or more of their starting body weight. These results significantly outperformed older weight loss medications and diet-only interventions, establishing semaglutide as a game-changing therapy.

Beyond weight loss numbers, the STEP trials measured improvements in cardiometabolic health markers including reduced blood pressure, better cholesterol profiles, and improved blood sugar control in participants with prediabetes. Patients also reported enhanced physical function, reduced joint pain, and better mental health outcomes. Real-world data since 2021 has confirmed these trial findings, with consistency across different healthcare settings and patient populations.

How Semaglutide Works: The GLP-1 Mechanism Behind Weight Loss

Semaglutide activates GLP-1 receptors in the brain, specifically in areas controlling hunger and satiety signals. This activation increases feelings of fullness at smaller meal portions, reduces cravings for high-calorie foods, and slows gastric emptying so nutrients stay in the stomach longer. The drug also improves insulin sensitivity and reduces inflammation, addressing multiple biological pathways that drive weight gain.

The genetic variations in GLP-1 receptor expression influence how effectively individuals respond to semaglutide therapy. PlexusDx's Precision Peptide Genetic Test identifies variants in the GLP1R gene (rs6923761) and other metabolic pathways (GIPR, FTO, MC4R) to predict treatment response and optimize dosing strategies. This personalized approach helps ensure patients receive the right compound at the right dose for their unique biology.

PlexusDx Compounded Semaglutide: Access and Affordability Since 2021

Since Wegovy's 2021 approval, access barriers including cost, insurance coverage delays, and supply shortages have limited patient options. PlexusDx addresses these challenges by offering compounded semaglutide injections from licensed 503A compounding pharmacies starting at $149 per month with no insurance required and no membership fees. Patients maintain consistent pricing across all dose levels—your dose may need to go up, but your price won't.

All 50 states now have access to PlexusDx semaglutide therapy, with HSA and FSA eligibility available. The company provides optional Precision Peptide Genetic Testing for $99 after the first month of treatment, enabling providers to make data-driven dosing decisions based on individual peptide pathway genetics. This combination of affordability, accessibility, and personalization represents how weight loss therapy has evolved since Wegovy's introduction.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How long has semaglutide been available as a weight loss medication?

Semaglutide received FDA approval specifically for weight management on June 4, 2021, though the drug had been used safely for diabetes since 2017. PlexusDx has provided compounded semaglutide injections to patients nationwide since entering the market, offering the same proven mechanism at substantially lower cost than brand-name alternatives.

What percentage of people lose weight on semaglutide therapy?

In the STEP 1 clinical trial, 86% of participants achieved at least 5% weight loss, while 69% lost 10% or more of their starting body weight. Average weight loss across all participants was 15.3% over 68 weeks, compared to just 2.6% in the placebo group, demonstrating semaglutide's consistent effectiveness across diverse populations.

Is PlexusDx semaglutide the same as brand-name Wegovy?

PlexusDx compounded semaglutide contains the identical active pharmaceutical ingredient as Wegovy, sourced from licensed 503A compounding pharmacies. The primary differences are price—starting at $149 per month versus brand-name costs—and direct access without insurance requirements or prior authorization delays.

Are there side effects to expect with semaglutide therapy?

Common side effects include nausea, vomiting, and diarrhea, typically mild and temporary as the body adjusts. More serious but rare side effects include pancreatitis or gallbladder issues. PlexusDx providers monitor patients throughout treatment and can adjust dosing strategies; genetic testing may also identify individuals with specific metabolic predispositions requiring closer monitoring.

How does the Precision Peptide Genetic Test improve semaglutide outcomes?

PlexusDx's genetic test identifies variants in GLP1R, GIPR, FTO, and MC4R genes that influence semaglutide response and optimal dosing. Testing 14 pathways and 150+ genetic insights helps providers personalize therapy, potentially improving weight loss results and reducing side effects by matching treatment to individual biology rather than using one-size-fits-all dosing.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves